风湿免疫科指南

订阅

MedSci主页 / 所有栏目 / 风湿免疫科指南

多发性硬化症治疗共识小组 (MSTCG)：对讨论问题的回答

2021-08-02 多发性硬化症治疗共识小组 Neurol Res Pract . 2021 Aug 6;3(1):44

多发性硬化症

多发性硬化症治疗共识小组 (MSTCG)：对讨论问题的回答

中文标题：

多发性硬化症治疗共识小组 (MSTCG)：对讨论问题的回答

发布机构：

多发性硬化症治疗共识小组

发布日期：

2021-08-02

简要介绍：

多发性硬化症治疗共识小组 (MSTCG)：对讨论问题的回答

相关资料下载：
[AttachmentFileName(sort=1, fileName=66.pdf)] GetToolGuiderByIdResponse(projectId=1, id=8632d1c00215237a, title=多发性硬化症治疗共识小组 (MSTCG)：对讨论问题的回答 , enTitle=, guiderFrom=Neurol Res Pract . 2021 Aug 6;3(1):44, authorId=0, author=, summary=多发性硬化症治疗共识小组 (MSTCG)：对讨论问题的回答, cover=, journalId=0, articlesId=null, associationId=1951, associationName=多发性硬化症治疗共识小组 , associationIntro=多发性硬化症治疗共识小组 (MSTCG), copyright=0, guiderPublishedTime=Mon Aug 02 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<p>多发性硬化症治疗共识小组 (MSTCG)：对讨论问题的回答</p>, tagList=[TagDto(tagId=972, tagName=多发性硬化症)], categoryList=[CategoryDto(categoryId=15, categoryName=风湿免疫科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=0, guiderKeyword=, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=1, guiderRegion=1, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=4833, appHits=132, showAppHits=0, pcHits=711, showPcHits=4699, likes=0, shares=8, comments=3, approvalStatus=1, publishedTime=Thu Aug 12 21:07:47 CST 2021, publishedTimeString=2021-08-02, pcVisible=1, appVisible=1, editorId=4754896, editor=fbzhang, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=4, createdBy=null, createdName=fbzhang, createdTime=Thu Aug 12 21:06:53 CST 2021, updatedBy=4754896, updatedName=fbzhang, updatedTime=Sat Jan 06 02:19:58 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=66.pdf)])
66.pdf
下载请点击：
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1056759, encodeId=8c6e1056e59ab, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfc84293490, createdName=13f0c37dm61暂无昵称, createdTime=Fri Oct 01 14:12:00 CST 2021, time=2021-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055386, encodeId=5ec51055386ff, content=看不懂, beContent=null, objectType=guider, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfc84293490, createdName=13f0c37dm61暂无昵称, createdTime=Mon Sep 27 15:28:51 CST 2021, time=2021-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1051863, encodeId=a7b2105186376, content=受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c905475903, createdName=湘雅科教, createdTime=Thu Sep 16 11:32:49 CST 2021, time=2021-09-16, status=1, ipAttribution=)]
    2021-10-01 13f0c37dm61暂无昵称

    谢谢分享

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1056759, encodeId=8c6e1056e59ab, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfc84293490, createdName=13f0c37dm61暂无昵称, createdTime=Fri Oct 01 14:12:00 CST 2021, time=2021-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055386, encodeId=5ec51055386ff, content=看不懂, beContent=null, objectType=guider, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfc84293490, createdName=13f0c37dm61暂无昵称, createdTime=Mon Sep 27 15:28:51 CST 2021, time=2021-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1051863, encodeId=a7b2105186376, content=受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c905475903, createdName=湘雅科教, createdTime=Thu Sep 16 11:32:49 CST 2021, time=2021-09-16, status=1, ipAttribution=)]
    2021-09-27 13f0c37dm61暂无昵称

    看不懂

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1056759, encodeId=8c6e1056e59ab, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfc84293490, createdName=13f0c37dm61暂无昵称, createdTime=Fri Oct 01 14:12:00 CST 2021, time=2021-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055386, encodeId=5ec51055386ff, content=看不懂, beContent=null, objectType=guider, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfc84293490, createdName=13f0c37dm61暂无昵称, createdTime=Mon Sep 27 15:28:51 CST 2021, time=2021-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1051863, encodeId=a7b2105186376, content=受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c905475903, createdName=湘雅科教, createdTime=Thu Sep 16 11:32:49 CST 2021, time=2021-09-16, status=1, ipAttribution=)]
    2021-09-16 湘雅科教

    受益匪浅

    0

相关指南

对符合免疫抑制治疗条件的多发性硬化症患者的疫苗接种建议：西班牙共识声明

暂未更新 · 2020-06-23

多发性硬化症患者的疾病调节药物和计划生育：海湾地区的共识

暂未更新 · 2020-06-23

2016 CMSC修订建议：标准化MRI协议和多发性硬化的诊断与随访

国际多发性硬化专家组(International Panel of MS) · 2016-03-01